Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 1:13:1310331.
doi: 10.3389/fonc.2023.1310331. eCollection 2023.

Editorial: Primary and acquired resistance in lung cancer

Rossella Bruno  1 , Michele Simbolo  2 , Iacopo Petrini  3
Affiliations
Editorial

Editorial: Primary and acquired resistance in lung cancer

Rossella Bruno et al. Front Oncol. .
No abstract available

Keywords: acquired resistance; immunotherapy; lung cancer; predictive biomarkers; primary resistance; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Primary and acquired resistance in lung cancer

References

    1. Villaruz LC, Socinski MA, Weiss J. Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine. Front Oncol (2023) 13:1124167. doi: 10.3389/fonc.2023.1124167 - DOI - PMC - PubMed
    1. Hendriks LE, Kerr KM, Menis J, Mok TS, Nestle U, Passaro A, et al. . Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol (2023) 34:339–57. doi: 10.1016/j.annonc.2022.12.009 - DOI - PubMed
    1. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. . Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med (2020) 382:41–50. doi: 10.1056/NEJMoa1913662 - DOI - PubMed
    1. Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer (2019) 121:725–37. doi: 10.1038/s41416-019-0573-8 - DOI - PMC - PubMed
    1. Christensen JG, Hallin J. The KRASG12D inhibitor MRTX1133 elucidates KRAS-mediated oncogenesis. Nat Med (2022) 28:2017–8. doi: 10.1038/s41591-022-02008-6 - DOI - PubMed

Publication types

LinkOut - more resources